The FDA approved islatravir-doravirine (Idvynso) as a standalone, single-tablet regimen for treating HIV in virologically ...
Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso ...
HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...
The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).
Switching to INSTI-based ART from protease inhibitors is associated with an increased risk for incident diabetes in treatment-experienced adults.
Switching From HIV Protease Inhibitors to Integrase Strand Transfer Inhibitors Tied to Diabetes Risk
HealthDay News — Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV, according to a study published online March ...
† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results